Looking beyond the small-molecule drugs and biologic treatments that have dominated therapeutic development over the past generation, GlaxoSmithKline’s ($GSK) all-encompassing R&D department is trying to get a jump on the future of medicine, and research chief Moncef Slaoui is betting that there’s a great deal of promise in drug-mimicking electronics.
{iframe}http://www.fiercebiotech.com/story/glaxosmithkline-rd-chief-touts-future-electroceuticals/2014-02-11{/iframe}